Table 1.
Clinical, demographic, and toxicity data. The cohort consisted of 629 participants. FOLFOX: chemotherapy regimen based on a combination of LV, 5FU (5-fluorouracil), and oxaliplatin; FOLFIRI: chemotherapy regimen based on a combination of LV, 5FU, and irinotecan; Cp: capecitabine; CPL: cis- or carboplatin; D: docetaxel; E: epirubicin; LV: leucovorin.
| Grade 3–5 | Grade 0–2 | Total | |||
|---|---|---|---|---|---|
| N | % | N | % | N | |
| Total | |||||
| Total cohort | 106 | 17 | 523 | 83 | 629 |
| Collection | |||||
| Prospectively | 92 | 15 | 522 | 85 | 614 |
| Retrospectively | 14 | 93 | 1 | 7 | 15 |
| Sex | |||||
| Female | 55 | 22 | 192 | 78 | 247 |
| Male | 51 | 13 | 331 | 87 | 382 |
| Ancestry | |||||
| Caucasian | 104 | 17 | 516 | 83 | 620 |
| Arab | 0 | 0 | 3 | 100 | 3 |
| African | 1 | 50 | 1 | 50 | 2 |
| Asian | 0 | 0 | 2 | 100 | 2 |
| Unknown | 1 | 50 | 1 | 50 | 2 |
| Treatment | |||||
| FOLFOX, FOLFIRI | 22 | 10 | 192 | 90 | 214 |
| 5FU +/−LV | 12 | 11 | 100 | 89 | 112 |
| 5FU, CPL +/−D,E | 36 | 30 | 86 | 70 | 122 |
| Other 5FU regimen | 10 | 28 | 26 | 72 | 36 |
| Cp | 26 | 18 | 119 | 82 | 145 |
| Toxicity category | |||||
| Hematologic toxicity | 58 | 9 | 571 | 91 | 629 |
| Gastrointestinal toxicity | 55 | 9 | 574 | 91 | 629 |
| Infection | 24 | 4 | 605 | 96 | 629 |
| Dermatologic toxicity | 15 | 2 | 614 | 98 | 629 |